
SAGE
SAGE Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
643.35M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
60.18M
EV
179.40M
EV/OCF(TTM)
--
P/S(TTM)
16.05
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
24.63M
+107.47%
-0.870
-43.14%
27.48M
+114.4%
-0.857
-28.43%
26.70M
+89.85%
-1.040
+4.26%
Estimates Revision
The market is revising Upward the revenue expectations for Sage Therapeutics, Inc. (SAGE) for FY2025, with the revenue forecasts being adjusted by 17.29% over the past three months. During the same period, the stock price has changed by 26.53%.
Revenue Estimates for FY2025
Revise Upward

+17.29%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+1.16%
In Past 3 Month
Stock Price
Go Up

+26.53%
In Past 3 Month
15 Analyst Rating

Wall Street analysts forecast SAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SAGE is 8.66 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
14 Hold
1 Sell
Hold

Current: 0

Low
5.00
Averages
8.66
High
12.00

Current: 0

Low
5.00
Averages
8.66
High
12.00
Scotiabank
George Farmer
Outperform -> Sector Perform
downgrade
$9.20
2025-07-07
Reason
Scotiabank
George Farmer
Price Target
$9.20
2025-07-07
downgrade
Outperform -> Sector Perform
Reason
Scotiabank analyst George Farmer downgraded Sage Therapeutics (SAGE) to Sector Perform from Outperform with a $9.20 price target. Supernus Pharmaceuticals (SUPN) has announced an agreement to acquire Sage through a tender offer for $8.50 per share in cash, payable at closing, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash, for total consideration of $12.00 per share in cash.
JPMorgan
Anupam Rama
Neutral
downgrade
$11
2025-06-22
Reason
JPMorgan
Anupam Rama
Price Target
$11
2025-06-22
downgrade
Neutral
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut.
Baird
Joel Beatty
Neutral
maintain
$7 -> $9
2025-06-21
Reason
Baird
Joel Beatty
Price Target
$7 -> $9
2025-06-21
maintain
Neutral
Reason
Baird analyst Joel Beatty raised the firm's price target on Sage Therapeutics to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its target to reflect its proposed acquisition price.
Piper Sandler
Overweight -> Neutral
downgrade
$9
2025-06-18
Reason
Piper Sandler
Price Target
$9
2025-06-18
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Sage Therapeutics to Neutral from Overweight with a price target of $8.50, down from $9, after the company entered into an agreement for Supernus to acquire it through a tender offer for $8.50 per share in cash plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash.
BofA
Underperform -> No Rating
downgrade
$12
2025-06-18
Reason
BofA
Price Target
$12
2025-06-18
downgrade
Underperform -> No Rating
Reason
BofA moved to No Rating from Underperform on Sage Therapeutics (SAGE) after the company announced a definitive agreement to be acquired by Supernus Pharmaceuticals (SUPN) for a total up to $12 per share. Sage shares are no longer trading on fundamentals given the deal announcement, the analyst tells investors.
Wedbush
Laura Chico
Hold
Reiterates
$6
2025-02-12
Reason
Wedbush
Laura Chico
Price Target
$6
2025-02-12
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for SAGE Therapeutics Inc (SAGE.O) is -2.49, compared to its 5-year average forward P/E of -4.94. For a more detailed relative valuation and DCF analysis to assess SAGE Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.94
Current PE
-2.49
Overvalued PE
-1.40
Undervalued PE
-8.47
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.38
Current EV/EBITDA
-0.59
Overvalued EV/EBITDA
9.56
Undervalued EV/EBITDA
-8.81
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
115.23
Current PS
5.86
Overvalued PS
290.01
Undervalued PS
-59.55
Financials
Annual
Quarterly
FY2025Q2
YoY :
+265.84%
31.66M
Total Revenue
FY2025Q2
YoY :
-51.25%
-54.25M
Operating Profit
FY2025Q2
YoY :
-51.73%
-49.65M
Net Income after Tax
FY2025Q2
YoY :
-53.53%
-0.79
EPS - Diluted
FY2025Q2
YoY :
-27.04%
-58.69M
Free Cash Flow
FY2025Q2
YoY :
+19.42%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+6.88%
-410.93
FCF Margin - %
FY2025Q2
YoY :
-86.80%
-156.83
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.6M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
443.0K
Volume
Months
3-6
1
2.0M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SAGE News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
16:17:48
Sage Therapeutics reports Q2 EPS (79c), consensus (94c)

2025-07-28 (ET)
2025-07-28
08:28:11
Supernus announces expiration of HSR waiting period for Sage Therapeutics

2025-07-01 (ET)
2025-07-01
09:29:16
Sage Therapeutics cutting over 330 jobs, Boston Globe reports


Sign Up For More Events
Sign Up For More Events
News
8.5
07-31NewsfilterSupernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
8.5
07-28NewsfilterSupernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
9.0
07-25NASDAQ.COMBiogen's ZURZUVAE Wins EMA Panel Backing For Postpartum Depression Treatment
Sign Up For More News
People Also Watch

NRIM
Northrim BanCorp Inc
81.100
USD
+0.30%

TRC
Tejon Ranch Co
18.410
USD
+0.27%

VBNK
Versabank
11.080
USD
-0.36%

MERC
Mercer International Inc
3.170
USD
-2.16%

CLDT
Chatham Lodging Trust
6.810
USD
+1.49%

ZVRA
Zevra Therapeutics Inc
11.480
USD
+0.35%

TKNO
Alpha Teknova Inc
4.350
USD
+1.16%

BAND
Bandwidth Inc
13.730
USD
+2.23%

VALU
Value Line Inc
38.420
USD
+2.29%

BIOX
Bioceres Crop Solutions Corp
3.370
USD
-6.13%
FAQ

What is SAGE Therapeutics Inc (SAGE) stock price today?
The current price of SAGE is 0 USD — it has decreased -0.23 % in the last trading day.

What is SAGE Therapeutics Inc (SAGE)'s business?

What is the price predicton of SAGE Stock?

What is SAGE Therapeutics Inc (SAGE)'s revenue for the last quarter?

What is SAGE Therapeutics Inc (SAGE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for SAGE Therapeutics Inc (SAGE)'s fundamentals?

How many employees does SAGE Therapeutics Inc (SAGE). have?
